Table 4.
ASSET meta-analysis of all possible NHL subtype subsets
| SNP (ref./alternate) | ||||
|---|---|---|---|---|
| OR | 95% CI | P-value | NHL subsets | |
| rs10936599 (T/C) | 1.13 | 1.06–1.20 | 4.33 × 10−5 | CLL/SLL, FL, MZL |
| rs2736100 (A/C) | 1.12 | 1.05–1.19 | 9.76 × 10−4 | CLL/SLL |
| rs7675998 (A/G) | 1.11 | 1.01–1.22 | 0.04 | CLL/SLL |
| rs9420907 (A/C) | 1.18 | 1.08–1.28 | 1.57 × 10−4 | CLL/SLL, MZL |
| rs8105767 (A/G) | 0.96 | 0.00–Inf. | 1.00 | MZL |
| rs755017 (A/G) | 0.89 | 0.79–1.01 | 0.06 | FL, MZL |
| rs11125529 (C/A) | 0.93 | 0.85–1.02 | 0.11 | CLL/SLL, DLBCL, MZL |
| rs6772228 (A/T) | 1.05 | 0.00–Inf | 1.00 | DLBCL, MZL |
| rs3027234 (T/C) | 1.05 | 0.96–1.16 | 0.30 | CLL/SLL, DLBCL |
| Genetic risk score | 2.47 | 1.82–3.35 | 7.19 × 10−9 | CLL/SLL |
Bold values designate statistically significant associations with a P-value < 0.05